Author:
Sigareva Lidia P.,Kokorina Arina A.,Kondartenko Albina A.,Slizhov Pavel A.,Ekaterina Ekaterina V.,Alexandrov Viktor N.,Solovyov Anton A.
Abstract
The basic principles of rational treatment of glomerulonephritis are considered, based on etiology, clinical manifestations and pathomorphological variants of its different forms. Today it has been established that glomerulonephritis can be primary (the etiology is usually unknown) and secondary, when the disease occurs against the background of concomitant pathology (systemic lupus erythematosus, vasculitis, hepatitis, oncological diseases, chronic viral and bacterial infections). The participation of various pathological, genetic and systemic factors in the development of various forms of glomerulonephritis has been shown. The characteristic clinical picture of manifestations of different forms of the disease and the degree of involvement of different renal structures in them are described. Against the background of the severity of the course and prevalence of various forms of glomerulonephritis, it is especially important to develop therapeutic approaches aimed at the full restoration of kidney function and cure of patients. One of such approaches is the use of biomedical cell products based on allogenic mesenchymal multipotent stromal cells and hematopoietic stromal cells. A number of studies have confirmed that the best results can be achieved with the use of cell products in complex therapies with standard treatment methods (use of cytostatics and steroid anti-inflammatory drugs) and alternative drug approaches (combination of monoclonal antibodies and polyenzyme drugs). At the same time, the use of standard and alternative techniques does not lead to a complete recovery of patients, but only transfers the course of the disease from the exacerbation phase to remission. The relevance of further development of biomedical cell products of allogeneic mesenchymal multipotent bone marrow stromal cells is shown, verification of their safety and efficacy in preclinical and clinical studies.
Reference59 articles.
1. Tomilina NA, Bikbetov BT. Jepidemiologija hronicheskoj pochechnoj nedostatochnosti i novye podhody k klassifikacii i ocenke tjazhesti hronicheskih progressirujushhih zabolevanij pochek. Terapevticheskij arhiv. 2005;77(6):87–92. (In Russ.)
2. Experimental models of renal disease
3. The etiology of glomerulonephritis: roles of infection and autoimmunity
4. Prihodina LS, Dlin VV, Ignatova MS. Glomerulonefrit pervichnyj. Detskaja nefrologija: rukovodstvo dlja vrachej. 2011:263–268.(In Russ.)
5. New Biologics for Glomerular Disease on the Horizon